Holen Sie sich die Stockscreener-App
4.91
0.41%
-0.02
Handel nachbörslich:
4.91
Schlusskurs vom Vortag:
$4.93
Offen:
$5
24-Stunden-Volumen:
857.74K
Relative Volume:
0.88
Marktkapitalisierung:
$147.23M
Einnahmen:
$160.43M
Nettoeinkommen (Verlust:
$-227.64M
KGV:
-0.0714
EPS:
-68.77
Netto-Cashflow:
$-170.79M
1W Leistung:
+9.84%
1M Leistung:
+28.53%
6M Leistung:
+74.73%
1J Leistung:
-65.45%
1-Tages-Spanne:
$4.81
$5.02
1-Wochen-Bereich:
$4.465
$5.18
52-Wochen-Spanne:
$1.38
$18.74
Agenus Inc Stock (AGEN) Company Profile
Firmenname
Agenus Inc
Sektor
Branche
Telefon
781-674-4410
Adresse
3 FORBES ROAD, LEXINGTON, MA
Vergleichen Sie AGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
4.91 | 147.23M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-28 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-04-22 | Eingeleitet | B. Riley FBR | Buy |
| 2016-10-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Bestätigt | Maxim Group | Buy |
| 2016-03-11 | Hochstufung | Maxim Group | Hold → Buy |
| 2015-12-16 | Eingeleitet | Jefferies | Buy |
| 2015-10-27 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-07-27 | Bestätigt | MLV & Co | Buy |
| 2015-06-11 | Eingeleitet | Oppenheimer | Outperform |
| 2015-01-12 | Bestätigt | Maxim Group | Buy |
| 2015-01-09 | Bestätigt | MLV & Co | Buy |
| 2015-01-09 | Bestätigt | Maxim Group | Buy |
| 2014-12-19 | Bestätigt | Maxim Group | Buy |
| 2014-05-08 | Bestätigt | Maxim Group | Buy |
| 2014-03-14 | Bestätigt | MLV & Co | Buy |
| 2013-10-08 | Bestätigt | Maxim Group | Buy |
| 2012-01-05 | Eingeleitet | William Blair | Outperform |
| 2011-12-01 | Eingeleitet | Global Hunter Securities | Buy |
Alle ansehen
Agenus Inc Aktie (AGEN) Neueste Nachrichten
# Agenus and Noetik partner to develop AI-powered cancer treatment biomarkers - Investing.com India
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock - MSN
Agenus Partners With Noetik to Advance Biomarker Discovery for Lead Cancer Immunotherapy Combo - MarketScreener
Agenus (AGEN) and Noetik Collaborate to Enhance Cancer Treatment - GuruFocus
Agenus, Noetik Enter Research Collaboration - Nasdaq
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology | AGEN Stock News - GuruFocus
AI Breakthrough: Agenus and Noetik Join Forces to Revolutionize Cancer Patient Selection Using Virtual Cell Models - Stock Titan
10 Most Undervalued Stocks to Buy for Under $5 - Insider Monkey
Zydus Life To Buy Agenus' US Facilities For $75 Million For Entry In Biologics CDMO - MSN
Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030 - GlobeNewswire Inc.
Is Zydus’s Agenus Deal Opportunistic Or Strategic? - insights.citeline.com
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
H.C. Wainwright Upgrades Agenus (AGEN) Stock to Buy - MSN
Agenus Announces Virtual Annual Shareholders Meeting - New Castle News
How to Join Agenus 2025 Virtual Shareholders Meeting: Complete Registration Guide - Stock Titan
Agenus climbs on deal with India’s Zydus for cancer therapy BOT/BAL - MSN
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from Analysts - Defense World
Baird Lifts Agenus (AGEN) PT to $6, Maintains Neutral Rating - MSN
Research Analysts Issue Forecasts for Agenus FY2027 Earnings - Defense World
HC Wainwright Forecasts Agenus’ Q3 Earnings (NASDAQ:AGEN) - Defense World
Zydus Lifesciences venture capital arm to acquire stake in Agenus for USD 16 million - Medical Dialogues
Zydus enters global biologics CDMO market with $75m facility acquisitions - BioProcess International
Agenus (NASDAQ:AGEN) Upgraded to “Buy” at HC Wainwright - Defense World
Agenus (NASDAQ:AGEN) Price Target Raised to $6.00 at Robert W. Baird - Defense World
Zydus Lifesciences to acquire India, Sri Lanka rights for Agenus cancer immunotherapy BOT/BAL - Medical Dialogues
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US - 뉴스와이어
Agenus Announces Strategic Collaboration with Zydus - TipRanks
Agenus IncSigns Partnership Agreements With Zydus Lifesciences - MarketScreener
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash OverhangAgenus (NASDAQ:AGEN) - Benzinga
Agenus Shares Rise After Upgrade From HC Wainwright - marketscreener.com
H.C. Wainwright upgrades Agenus stock on strategic collaboration - Investing.com Australia
H.C. Wainwright upgrades Agenus stock on strategic collaboration By Investing.com - Investing.com South Africa
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade - Yahoo Finance
Agenus (AGEN) Price Target Raised by Baird as Neutral Rating Mai - GuruFocus
Agenus (AGEN) Price Target Raised by Baird as Neutral Rating Maintained | AGEN Stock News - GuruFocus
Agenus (AGEN) Upgraded to 'Buy' by HC Wainwright & Co. | AGEN St - GuruFocus
HC Wainwright & Co. Upgrades Agenus (AGEN) - Nasdaq
Agenus (AGEN) Stock Price Target Increased by Baird | AGEN Stock News - GuruFocus
Agenus and Zydus sign agreements for botensilimab and balstilimab - Yahoo Finance
Zydus gets rights for next gen I-O platforms from Agenus - The Pharma Letter
HC Wainwright Upgrades Agenus to Buy From Neutral, $25 Price Target - marketscreener.com
Agenus (AGEN) Boosted to Buy Following Key Zydus Partnership | A - GuruFocus
Agenus (AGEN) Boosted to Buy Following Key Zydus Partnership | AGEN Stock News - GuruFocus
Zydus signs deal with Agenus for next-gen cancer immunotherapies - Healthcare Radius
Zydus to enter global biologics CDMO business to accelerate development of innovative therapies - Pharmabiz.com
Jane Street Group LLC Raises Stock Position in Agenus Inc. (NASDAQ:AGEN) - Defense World
Zydus to enter global biologics CDMO business Plans to acquire Agenus’ U.S. manufacturing facilitiesto accelerate development of innovative therapies - APN News
Zydus to acquire Agenus’ US manufacturing facilities, forays into global biologics CDMO business - Indian Pharma Post
Zydus Lifesciences acquires Agenus Biologics facilities in US, enters global CDMO market - Express Pharma
Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies - StreetInsider
Agenus inks $141M deal with Zydus for cancer drugs, facilities By Investing.com - Investing.com South Africa
Finanzdaten der Agenus Inc-Aktie (AGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.02%
1.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):